Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-ii save search
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
|
| O: 10.02%
H: 0.0%
C: 0.0%
bb-301 first positive biopharma for trial opmd study
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
EOLS | News | $11.56 -0.69% -0.69% 340K
|
Health Technology
|
| O: -1.49%
H: 0.0%
C: 0.0%
jeuveau publication for study
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | News | $2.45 -5.77% -6.12% 17K
|
Health Technology
|
| O: 4.43%
H: 0.0%
C: 0.0%
dm199 first stroke treatment for trial therapeutics
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | News | $13.03 3.66% 3.53% 1.8M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
Published: 2024-04-16 (Crawled : 00:00) - biospace.com/
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
tezspire copd
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
PTCHF | $2.78 19.97% 560
|
n/a
| Email alert
Add to watchlist
lyt-100 fibrosis trial
AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
Published: 2024-04-15 (Crawled : 12:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
avb-101 first dementia for trial
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Published: 2024-04-10 (Crawled : 14:00) - biospace.com/
AMLX | $1.97 -1.5% -1.52% 1M
|
|
| O: -2.62%
H: 1.54%
C: -5.38%
amx0035 control pancreatic ongoing pharmaceuticals trial
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
Published: 2024-04-04 (Crawled : 11:00) - biospace.com/
ACHL | $0.795 -2.39% -2.45% 190K
|
Manufacturing
|
| O: -16.22%
H: 0.99%
C: -7.89%
first melanoma update therapeutics advanced
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
Published: 2024-04-03 (Crawled : 19:00) - biospace.com/
MRNA | News S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -0.59%
H: 2.09%
C: -1.74%
rna-3927 mrna therapy
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.13%
H: 0.0%
C: 0.0%
cancer trial initiated
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
ALGS | $0.781 -0.76% -0.77% 240K
|
Health Technology
|
| O: 2.25%
H: 4.0%
C: 1.0%
alg-0550 first therapeutics study
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
VRTX | $393.51 0.1% 0.1% 950K
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: 0.0%
vx-147 disease kidney treatment trial
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
NTRA | $87.19 -3.48% -3.6% 1.1M
|
Health Services
|
| O: -0.6%
H: 2.8%
C: 2.25%
cancer trials trial
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
Published: 2024-03-27 (Crawled : 23:00) - biospace.com/
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.78%
H: 0.4%
C: -0.49%
ren026 fda study
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
Published: 2024-03-15 (Crawled : 12:30) - biospace.com/
CYBN | $0.3699 -1.47% 1.05% 1.7M
|
n/a
|
| O: 1.59%
H: 7.78%
C: 5.55%
cyb004 study
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
Published: 2024-03-14 (Crawled : 12:30) - biospace.com/
CYBN | $0.3699 -1.47% 1.05% 1.7M
|
n/a
|
| O: 7.14%
H: 5.53%
C: -4.67%
cyb003 fda positive meeting program design
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Published: 2024-03-08 (Crawled : 14:30) - biospace.com/
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: 1.14%
H: 5.63%
C: -0.39%
treatment pharmaceuticals study
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
Published: 2024-03-06 (Crawled : 14:30) - biospace.com/
MAIA | $1.96 -1.01% 0.0% 68K
|
|
| O: 9.46%
H: 4.94%
C: -9.26%
lung cancer cell treatment
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
Published: 2024-03-06 (Crawled : 14:30) - biospace.com/
DTIL | $10.77 -6.43% -6.87% 71K
|
Health Technology
|
| O: 1.56%
H: 3.55%
C: 0.81%
precision approval arcus program trial
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.